Shamburg News · 8-K filed Nov 5, 2026, 9:15 AM EST
MetaVia Reports Interim Phase 1 Part 3B Data for DA-1726 Showing Liver Fat and Weight Reductions
MTVA · MetaVia Inc.
- Reg FD disclosure
- Other event
- Other
- Materiality: medium
On November 5, 2026, MetaVia Inc. announced positive interim data from Part 3B of its Phase 1 trial of DA-1726, presented at the Precision Liver Symposium on November 4, 2026. The company reported a 68% placebo-adjusted reduction in liver fat and a 13.5% placebo-adjusted body weight reduction after 16 weeks of once-weekly DA-1726 treatment. The company also posted an updated corporate presentation and furnished the press release and presentation under Regulation FD and Item 8.01.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001104659-26-123110.
Written from the filing by Shamburg Markets. Figures are as reported by the company.